Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial

INTRODUCTION: In the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT; ClinicalTrials.gov number NCT01994889), tafamidis reduced the risk of all-cause mortality in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) by 30% versus placebo. Median overall survival was not ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Benjamin, Alvir, Jose, Stewart, Michelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584686/
https://www.ncbi.nlm.nih.gov/pubmed/32524297
http://dx.doi.org/10.1007/s40119-020-00179-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584686/
https://www.ncbi.nlm.nih.gov/pubmed/32524297
http://dx.doi.org/10.1007/s40119-020-00179-2

Ejemplares similares